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Abstract
Introduction:  Patients with bipolar affective disorder can be effectively managed with
pharmacological intervention. This case report describes a pregnant woman with a ten-year history
of bipolar affective disorder that was being treated with lithium, haloperidol and benztropine.
Case presentation: The patient had a normal pregnancy, but developed an elevated blood
pressure and started to lose weight at 36 weeks of gestation. During pregnancy, plasma
concentrations of choline and phosphatidylcholine are increased to meet the demands of the
foetus. However, our findings in this case included depletion of plasma choline and
phosphatidylcholine concentrations. Other unusual outcomes included low placental weight and
low infant birth weight.
Conclusion: This report suggests that the pharmacological management of this patient could
possibly account for the findings.
Introduction
Choline is a nutrient that is a precursor of phosphatidyl-
choline and the plasma concentrations of both nutrients
are controlled by endogenous synthesis and dietary intake
[1]. Both are important for the efficient turnover of lipids
from the liver and blood. Choline is also important for
the control of plasma homocysteine concentration and is
the precursor of the neurotransmitter acetylcholine,
which is important for the proper functioning of choliner-
gic neurons peripherally and in the brain.
Patients with bipolar affective disorder are effectively
managed with pharmacological intervention, such as lith-
ium, haloperidol and benztropine, but studies on the
influence of these drugs on plasma choline and phos-
phatidylcholine concentrations are limited. There is evi-
dence that lithium can decrease the plasma availability of
these important cell components [2,3], but whether this
translates into depletion in the brain supply remains
questionable [4].
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When women with bipolar affective disorder become
pregnant, pharmacological management is complicated
because of possible risks to the foetus from the use of
medications. Lithium, for example is classified as a cate-
gory D drug [5], that is, having the potential to cause foe-
tal malformations, including foetal cardiac
malformations [6,7]. However in the case of pregnant
patients with affective disorder, the benefits of therapy can
outweigh the risks. We report on the pregnancy outcomes
of a patient with bipolar affective disorder treated with
mood stabilizers in the antenatal clinic of the University
Hospital of the West Indies.
Case presentation
The patient was a 25-year-old gravida 2, presenting to the
antenatal clinic at 13 weeks gestational age. Medical his-
tory indicated that the patient was diagnosed with bipolar
disorder ten years prior to this pregnancy. She was effec-
tively managed with lithium carbonate (500 mg b.i.d.),
haloperidol (Haldol®5 mg b.i.d.) and benztropine
(Cogentin®, 2 mg b.i.d.) prior to pregnancy and the regi-
men was continued through the pregnancy. Plasma con-
centrations of the prescribed medication were not
assessed. At 12 weeks gestation, the patient described her
appetite as good, with two full meals and three snacks per
day. Her pregnancy booking BMI was 21.99 and plasma
haemoglobin (Hb) was normal (11.4 mg/dL). Her hae-
moglobin phenotype status is AA and she was both HIV
and VDRL negative. The patient also reported regular sup-
plementation with multivitamins specific for pregnancy
(Materna®). Her blood pressure was normal at the begin-
ning of the pregnancy at 110/70 mmHg and remained
normal until about 36 weeks of gestation. The weight gain
from 15 to 36 weeks of gestation was 6.9 Kg and her Hb
remained in the normal range throughout the pregnancy.
She then started to lose weight moving from 73.1 Kg at 36
weeks (+ 5 days) to 71.4 Kg at 38 weeks (+ 5 days) and
recorded an elevation in blood pressure from week 37
until week 38. Her blood studies at 37 weeks were all nor-
mal (Table 1).
She was admitted to the antenatal ward at 38 weeks + 5
days and labour was induced, however due to failure to
progress, a caesarean section was performed with the birth
of a male infant at 39 weeks. The infant's birth Apgar
scores were good: 9 at one minute and 10 at 5 minutes.
The infant's birth weight was 2500 g, which is below the
mean for a term baby in the Jamaican population [8].
Both infant and mother were discharged after three days
and no follow-up data of either was collected.
The patient in this study was taken from a pool of sixteen
women who were followed through all three trimesters of
pregnancy. In order to make further assessment of infant
outcomes in this case, we selected other women from the
larger study that were similarly matched in gestation age,
weight gain, blood pressure, haemoglobin status and
infant gestational age at birth (Table 2). The most distinc-
tive differences between these other women and this
patient were the lower birth weight of the infant (30%
less) and lower placental weight (42% less).
We measured both fasting plasma phosphatidylcholine
and choline through the three trimesters of pregnancy
(Table 3). For this patient, comparison between the data
from trimester 1 (week 10–13) to trimester 3 (week
34–37) showed that plasma phosphatidylcholine concen-
tration decreased by 22% during this period, while the
plasma choline decreased by 38%. Comparison of the
Table 2: Comparison of variables between the patient with 
bipolar affective disorder and control patients.
Variable Bipolar patient. Means ± S.D. N = 3
Age/yrs 25 29 ± 9
Height/cm 173.5 164.8 ± 7.2
BMI 22 26.8 ± 2.3
Weight Gain/Kg 6.9 6.5 ± 1.0
13 weeks Systolic/mmHg 100 103 ± 15
22 weeks Systolic/mmHg 100 120 ± 10
36 weeks Systolic/mmHg 110 110 ± 10
13 weeks Diastolic/mmHg 60 63 ± 6
22 weeks Diastolic/mmHg 60 73 ± 6
36 weeks Diastolic/mmHg 80 77 ± 15
1st trimester Hb (g/dl) 11.4 14.2 ± 3.7
2nd trimester Hb (g/dl) 11.4 11.4 ± 1.1
3rd trimester Hb (g/dl) 11.9 11.2 ± 0.3
Parity 2 2 ± 2
Gestational age (days) 272 273 ± 2
Birth weight (g) 2500 3573 ± 133
Placental weight (g) 350 607 ± 51
Crown Heel length (cm) 51 48.5 ± 3.0
Head Circumference (cm) 32 33.6 ± 0.7
Ponderal index (g/cm3) 18.8 32 ± 7.1
Head 
Circumference:length 
ratio
62.7 69.5 ± 3.0
Placenta: Birth weight 
ratio
14 17 ± 0.8
The patient with bipolar affective disorder had lower infant birth 
weight and lower placental weight, resulting in lower ponderal index 
and placenta:birthweight ratio.
Table 1: Haematological indexes measured for bipolar affective 
disorder patient
Sodium 135 mmol/l Globulin 31 g/l
Potassium 4.7 mmol/l Direct Bilirubin 7 umol/l
Urea 1.9 mmol/l Total Bilirubin 22 umol/l
Creatinine 33 umol/ml Alkaline Phosphotase 85 IU/l
Uric acid 0.18 mmol/l G.G.T. 7 IU/l
Total protein 63 mmol/l S.G.O.T. 31 IU/l
Albumin 32 g/l PT 13.8/12.6
PTT 32.8/30.6Journal of Medical Case Reports 2008, 2:55 http://www.jmedicalcasereports.com/content/2/1/55
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controls showed the expected increase in plasma choline
and phosphatidylcholine concentrations.
Conclusion
We found that in the case of our patient, there was an unu-
sually low placental weight and a low infant birth weight
when compared with data recorded from three control
patients and from previous studies of our population [8].
These previous studies also recorded an association of low
birth weight infants with low haemoglobin concentra-
tions, especially during the first trimester. However, this
was not a factor in this case, as the patient maintained
normal plasma concentrations of haemoglobin through-
out the pregnancy.
Low weight gain during pregnancy is another risk factor
that contributes to low infant birth weight [9]; however,
the control patients that experienced similar weight gain
did not give birth to low birth weight infants. Although
our comparisons are limited by the lack of dietary intake
information, previous reports have confirmed that mood
stabilizers can contribute to low birth weight outcome
[10].
On further comparison of this patient with controls, it
appeared that there was a decrease in plasma choline and
phosphatidylcholine concentrations in this patient. Both
nutrients are especially important during pregnancy and
are actively transported to the foetus [1,11]. The decreases
in plasma concentrations of these nutrients in our patient
were unexpected, as plasma concentrations of both are
increased during pregnancy [12,13], possibly to ensure
adequate supply to the foetus. Phosphatidylcholine, for
example, supplies important long chain polyunsaturated
fatty acids, and deficiency of polyunsaturated fatty acids
to the foetus is a known risk factor for negative foetal out-
comes such as low birth weight [14]. Furthermore, animal
studies have demonstrated that inadequate maternal sup-
ply of these nutrients impairs cognitive and memory func-
tions of pups and that dietary supplementation with these
nutrients during pregnancy can prevent these effects
[1,15].
Our data analysis was limited by the lack of information
on the actual amounts of choline and phosphatidylcho-
line that were consumed by this patient during pregnancy
and therefore whether inadequate dietary intake contrib-
uted to the unexpected depletions. However, previously
documented evidence supports negative influences of at
least one of the drugs involved (lithium) on these nutri-
ents. We therefore conclude that there is need for further
studies to clarify the causal associations between drug
therapy, maternal outcomes, foetal outcomes and the
availability of these nutrients in patients being treated for
bipolar affective disorder. Whether benefits could be
derived from dietary supplementation with choline and
phosphatidylcholine should also be considered.
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